Regulus Therapeutics Reports Multiple Material Events
| Field | Detail |
|---|---|
| Company | Regulus Therapeutics Inc. |
| Form Type | 8-K |
| Filed Date | Jun 25, 2025 |
| Risk Level | high |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, delisting, governance, change-of-control
TL;DR
Regulus Therapeutics filed an 8-K detailing asset changes, potential delisting, control shifts, and officer changes.
AI Summary
Regulus Therapeutics Inc. filed an 8-K on June 25, 2025, reporting several material events as of June 24, 2025. These include the completion of an acquisition or disposition of assets, a notice of delisting or failure to meet listing rules, material modifications to security holder rights, a change in control of the registrant, and changes in directors or officers. The filing also covers amendments to articles of incorporation or bylaws and financial statements.
Why It Matters
This 8-K filing indicates significant corporate actions at Regulus Therapeutics, potentially impacting its stock listing, control, and governance structure.
Risk Assessment
Risk Level: high — The filing mentions potential delisting and changes in control, which are significant risk factors for investors.
Key Players & Entities
- Regulus Therapeutics Inc. (company) — Registrant
- June 24, 2025 (date) — Date of earliest event reported
- June 25, 2025 (date) — Date of report
FAQ
What specific assets were involved in the completion of an acquisition or disposition?
The filing does not specify the details of the assets involved in the acquisition or disposition.
What are the reasons for the notice of delisting or failure to satisfy a continued listing rule?
The filing does not provide specific reasons for the notice of delisting or failure to satisfy a continued listing rule.
What are the material modifications to the rights of security holders?
The filing does not detail the specific material modifications to the rights of security holders.
What triggered the change in control of Regulus Therapeutics Inc.?
The filing does not specify the event or transaction that led to the change in control.
Are there any new appointments or departures of directors or officers mentioned?
The filing indicates changes in directors or officers, but does not name specific individuals or their roles.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 25, 2025 regarding Regulus Therapeutics Inc..